FSTL1 and metastatic prostate carcinoma: Unlike ligands, soluble antagonists in metastatic prostate cancer patients are consistently increased in patients with CHRD at 12%, NOGGIN, SOSTDC1, FSTL1 at 7% and GREM2 at 6% of patients (Figure S1A).